Stockscreener 앱 받기
192.45
1.31%
-2.55
시장 영업 전:
192.65
0.20
+0.10%
Abbvie Inc 주식(ABBV)의 최신 뉴스
A New Playbook for Mid-Cap Biotechs: Glenmark's $700M Oncology Deal with AbbVie Signals Strategic Shifts - AInvest
The Smartest Dividend Stocks to Buy With $300 Right Now - The Motley Fool
A Drop of Innovation: AbbVie's Omega-3 Eye Drops and the Disruption of Dry Eye Care - AInvest
Refresh Releases First of its Kind Eye Drop for Dry Eyes - MarketScreener
AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada - MarketScreener
India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal - Reuters
AbbVie and Genmab’s Promising Phase 3 Study for DLBCL: A Potential Game-Changer - The Globe and Mail
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now? - Yahoo Finance
AbbVie Beats Investor Class Suit Claiming Humira Kickbacks (2) - Bloomberg Law News
AbbVie & IGI Enter Global Licensing Agreement for Trispecific Antibody - Contract Pharma
Dividend Roundup: CVS Health, Procter & Gamble, AbbVie, Colgate-Palmolive, and more (PG:NYSE) - Seeking Alpha
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Dividend Investors: Don't Be Too Quick To Buy AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend - simplywall.st
AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody - pharmaphorum
FiDi-based drug company inks $1B oncology deal with AbbVie - Crain's New York Business
Glenmark-AbbVie Deal Lifts Optimism on India’s Biotech Stocks - Bloomberg
Glenmark Pharma shares surge after its U.S arm, AbbVie ink pact for investigational cancer drug - The Hindu
India’s Glenmark Pharma shares hit record high on AbbVie cancer drug deal - Investing.com
Glenmark Unit to License Blood Cancer Drug to Abbvie for $700 Million Upfront - Bloomberg
Glenmark Pharma jumps on unit's cancer treatment licensing deal with AbbVie - MarketScreener
AbbVie Shares Climb on $700 Million Licensing Deal with IGI Therapeutics - MSN
AbbVie (ABBV) Laps the Stock Market: Here's Why - Yahoo Finance
Abbvie gains rights to IGI’s trispecific ISB-2001 in $1.9B+ deal - BioWorld MedTech
AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025 - insights.citeline.com
Wall Street Stunned: AbbVie Drops $700M on a Little-Known Indian Cancer Drug - Yahoo Finance
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers - Stocktwits
Why Is AbbVie Stock Trading Higher On Thursday? - Benzinga
AbbVie Strikes $2B Licensing Deal with IGI Therapeutics - USA Herald
AbbVie expands oncology pipeline with exclusive licensing agreement - The Business Journals
AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma - MedCity News
Glenmark unit clinches $700mn licensing deal for its cancer drug | Company Business News - Mint
Pfizer and AbbVie Advance Pediatric Antibiotic Study with ATM-AVI - TipRanks
AbbVie Pays Up To $2B For Oncology Licensing Agreement - Law360
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody - Yahoo Finance
AbbVie to pay $700M for trispecific drug from Ichnos Glenmark - BioPharma Dive
AbbVie stock jumps after $700 million licensing deal with IGI Therapeutics - Investing.com
Glenmark arm inks $700 million licensing deal with US-based AbbVie - Business Standard
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B - BioSpace
India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact - Reuters
AbbVie and Ichnos Glenmark sign licensing deal for trispecific antibody - Seeking Alpha
AbbVie and Ichnos Glenmark ink antibody license deal - The Pharma Letter
AbbVie bets on 'new frontier' in immuno-oncology with $1.9B trispecific deal - FirstWord Pharma
AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody - MarketScreener
AbbVie Signs Deal With IGI Therapeutics To Develop ISB 2001 For Oncology, Autoimmune Diseases - Nasdaq
AbbVie licenses IGI’s multiple myeloma treatment in $1.9 billion deal - Investing.com
AbbVie Pays $700M Upfront for Revolutionary Triple-Target Cancer Drug in Billion-Dollar Deal - Stock Titan
Tax Court Breaks New Ground on the Deductibility of Termination Fees with AbbVie Ruling - proskauertaxtalks.com
Pharmaceutical giant AbbVie wants to expand its presence in Worcester - Worcester Telegram
Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV) - Insider Monkey
10 High Growth Dividend Paying Stocks to Buy - Insider Monkey
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term - Yahoo Finance
Top Stock Reports for Alphabet, AbbVie & Walt Disney - Yahoo Finance
AbbVie snaps up CAR-T company in a deal worth $2.1 billion | STAT - STAT
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock - Yahoo Finance
Here's Why AbbVie (ABBV) is a Strong Momentum Stock - Nasdaq
Is AbbVie the Best Dividend Stock in Big Pharma Today? - MSN
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie (NYSE:ABBV) migraine drug update boosts biotech pipeline strength S&P 500 - Kalkine Media
AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant - Yahoo Finance
AbbVie's migraine drug meets main goal in head-to-head study with topiramate - Reuters
AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial - Benzinga
AbbVie’s atogepant achieves superiority in migraine prevention - The Pharma Letter
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - PharmaLive
AbbVie (ABBV) Sees Success with Migraine Drug Atogepant in Late-Stage Trial - GuruFocus
AbbVie Stock (ABBV) Dips: A Buying Opportunity for its 3.55% Dividend Yield? - Daily Chhattisgarh News
Hidradenitis Suppurativa Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte, CSL Behring - Barchart.com
AbbVie succeeds in late-stage migraine treatment trial (ABBV) - Seeking Alpha
AbbVie’s migraine drug meets main goal of late-stage study - 1470 & 100.3 WMBD
AbbVie (ABBV) Reports Positive Results from Migraine Study | ABBV Stock News - GuruFocus
AbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane - Nasdaq
AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - Investing News Network
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
AbbVie’s atogepant shows superior results in migraine prevention trial By Investing.com - Investing.com Canada
2.93%
자본화:
|
볼륨(24시간):